Diagnosis and monitoring trackers

Diagnosis & monitoring trackers

▶️ NVision Imaging

NVision Imaging (Germany) engineers quantum-powered medical imaging technologies 🩻🧑‍⚕️ that deliver deeper, more precise MRI data for researchers and clinicians. Their unique hyperpolarization device Polaris enables fast, simple, scalable imaging of metabolism at the cellular level. With hyperpolarized MRI, NVision is paving the way for earlier detection, faster treatment assessment, and better risk profiling in oncology, cardiology, neurology, and beyond.

On May 1, 2025, Polaris was temporarily installed at University College London (UCL) as part of CHARM (Calibration of Hyperpolarized metAbolic MR), that is
a UK–Germany collaboration that aims to make hyperpolarized MRI clinically scalable through standardized calibration methods, phantoms, and reliable polarizer technology. During the 3️⃣-week deployment, Polaris supported over 1️⃣0️⃣0️⃣ hyperpolarization experiments and demonstrated consistent performance.

Moreover, so far 2️⃣ POLARIS systems have been used across:

• Technical University of Munich (TUM), Germany,

• Institute for Bioengineering of Catalonia (IBEC), Spain,

• University of California San Francisco (UCSF), USA,

• MD Anderson Cancer Center (MDA), USA,

• University College London (UCL), UK, and

• Memorial Sloan Kettering Cancer Center (MSK), USA.

On December 9, 2025, NVision announced that Memorial Sloan Kettering Cancer Center (MSK) is using its device, Polaris, in oncological preclinical studies (NVision Metabolic MRI Technology Advances Oncology Research). This marks the first use of NVision’s technology at a leading cancer research institution to monitor treatment efficacy in targeted therapies. In particular,

• ✅ MSK will integrate Polaris into its MRI workflow across several preclinical studies, focusing on tumor areas such as pancreatic cancer, prostate cancer, breast cancer, and brain tumors. Researchers will investigate the role of hyperpolarized metabolic MRI in both cancer diagnosis and treatment monitoring of drug and radiation therapies.

Polaris boosts the MRI signal of sugars over 1️⃣0️⃣,0️⃣0️⃣0️⃣x through a process known as hyperpolarization, making it possible for standard MRI systems to measure cell metabolism in real time.

• ✅ It is the 1️⃣st commercially available quantum-based polarizer, using parahydrogen-induced polarization (PHIP) to generate hyperpolarized sugars in under 3 minutes. Unlike standard anatomical MRI, which typically only shows structural changes, hyperpolarized metabolic MRI reveals shifts in tumor metabolism directly.

• ✅ The ability to measure metabolic changes could allow for faster cancer diagnosis, more accurate staging, and show sooner whether a therapy is working or not.

Moreover, NVISION is part of the Q-AID and QuE-MRT projects.

• ✅ Q-AID’s mission is to integrate quantum-enhanced hyperpolarized MRI imaging with advanced AI, opening new possibilities for diagnosis and treatment of cancer, Alzheimer’s disease, and multiple sclerosis.

• ✅ QuE-MRT is focused on building an end-to-end clinical platform for quantum-enhanced hyperpolarized metabolic MRI, including R&D work on the polarizer and MRI acquisition methods, preclinical research on cancer models, regulatory effort towards clinical studies in Germany and ultimately running clinical studies on 3️⃣ different cancer patient populations.

▶️ FoodMarble | Breath Tester for Better Digestive Health

FoodMarble (Ireland) is the world’s first personal digestive tracker 🍲, designed to help people who experience digestive discomfort better understand how food affects them. Its hand-held, affordable breath analysis device and companion app are based on the most advanced techniques used in gastroenterology departments worldwide, with precision clinical-grade sensors for hydrogen and methane. Together, they give people clarity around their diet, reveal what works for their unique digestive system, and help them take control.

Through the FoodMarble Healthcare platform, gastroenterologists, clinics and healthcare professionals can support the diagnosis and management of conditions such as Irritable Bowel Syndrome (IBS) and Small Intestinal Bacterial Overgrowth (SIBO).

On August 29, 2025, a 🆕 study in Clinical and Translational Gastroenterology has demonstrated that a first-of-its-kind breath test device from FoodMarble, used as part of an app-guided program, enables clinically meaningful reductions in common digestive symptoms after only a single-week of dietary change (First-of-Its-Kind Digestive Breath Device Shown to Have Clinically Meaningful Benefits as Part of New Gut Health Program).

• ✅ The study has shown that the app successfully helped individuals with IBS to reduce their intake of FODMAPs (fermentable oligo-, di-, mono-saccharides, and polyols—short-chain carbohydrates), which are highly fermentable foods. This led to notable reductions in their fermentation levels, as measured using the device. This in turn corresponded with reductions in their digestive symptoms, indicating that our ability to digest different types of food can be conveniently measured from the air we breathe.

• ✅ The device measures levels of hydrogen and methane on the breath. These molecules are produced when food hasn't been fully digested. The food is instead fermented by our gut bacteria, producing these molecules, which can accumulate provoking symptoms. These gases also diffuse into the blood and travel to the lungs, which means they can be measured on the breath.

• ✅ To conclude, this 🆕 study demonstrated that meaningful improvements can be achieved in just one week of dietary change (for people experiencing IBS) using a structured, self-guided protocol. It also showed that breath data can track real-time responses, helping patients understand their unique digestive patterns and make informed dietary decisions. This builds on a previous FoodMarble study at Johns Hopkins Medicine, that supports remote patient monitoring (RPM) as a scalable home-based solution for digestive health, to expand access and eliminate common care barriers, such as travel and wait times.

▶️ Qardio - #1 Blood Pressure Management Solution

Qardio (US, UK) specializes in remote health monitoring. Its platform enables Qardio partners 🫀 to quickly and efficiently track, analyze, and triage large patient populations, with improved workflows and continuous patient engagement, under all conditions. QardioArm is a Bluetooth-enabled blood pressure monitor that measures systolic and diastolic pressure as well as heart rate, mean arterial pressure, and pulse pressure. It also has irregular heartbeat detection. And Qardio+ is a comprehensive health monitoring system taking home health monitoring to the next level.

In 2023, Qardio announced the launch of logic-driven patient assessments on QardioMD, its virtual care dashboard for healthcare professionals. QardioMD is making it quick and hassle-free to create and deliver assessments tailored to individual patients. Clinical staff can either design customized assessments or opt to use the default assessments provided by the American Heart Association. Once created, assessments are seamlessly integrated into patient care plans. QardioMD allows patient assessments to be part of an initial welcome series or scheduled by time/date, test frequency, or diagnostic results.

Moreover, QardioMD employs sophisticated algorithms, logic, and rules, enabling healthcare professionals to assign follow-up actions in response to specific assessment results. For instance, based on the patient data collected in an assessment, QardioMD allows clinicians to implement logic that can prompt additional assessment questions or communicate important messages to patients.

Excitingly, Qardio is actively working on integrating AI into future iterations of the QardioMD platform.

▶️ Prism Labs | Mobile Body Composition & Health Tracking

Prism Labs | Mobile Body Composition & Health Tracking (US) has developed the most comprehensive and precise methodology for measuring body composition 🏃 and tracking changes using just a single smartphone. Its ten-second scan produces a millimeter-accurate 3D model of the body, delivering an immediate "wow effect."

Prism is revolutionizing health tracking through cutting-edge 3D bodymapping and body composition analysis. By using only a standard mobile phone camera, Prism Labs enables users to generate accurate, millimeter-precise 3D bodymaps in just ten seconds – no special equipment or trained staff required. Powered by advanced AI and computer vision, Prism’s platform delivers

• 👉 comprehensive body insights,

• 👉 including body fat percentage, lean mass 💪, and detailed circumference measurements,

• 👉 allowing individuals and fitness professionals to monitor progress and make data-driven health decisions.

On May 6, 2025, Prism Labs and Fit3D, a leader in 3D body scanning technology, has officially launched its groundbreaking product, SNAP, powered by Prism Labs’ cutting-edge mobile body composition analysis technology (Fit3D and Prism Labs Announce Revolutionary SNAP Body Scanner for Tablets). This partnership marks a significant step in democratizing access to professional-grade 3D body scanning for businesses of all sizes.

• 👉 SNAP is a tablet-based 3D scanning solution designed to provide the same high-quality body composition analysis and insights as Fit3D’s ProScanner but without the need for expensive hardware.

• 👉 By leveraging Prism Labs’ advanced mobile platform, SNAP offers unparalleled accuracy and ease of use in a significantly less expensive hardware investment.

• 👉 The app runs on approved Samsung Galaxy tablets with price points as low as 💲2️⃣0️⃣0️⃣, making it an affordable and accessible option for fitness centers, medspas, and other wellness businesses at a fraction of the cost.

• 👉 The combination of Prism Labs’ and Fit3D’s proprietary algorithms ensure that SNAP delivers precise body composition metrics comparable to gold-standard methods like DXA scans. These include measurements such as body fat percentage, lean mass, waist-to-hip ratio, and more—all processed seamlessly through the Fit3D Dashboard.

• 👉 Both the Prism and Fit3D platforms have been extensively validated by independent laboratories and have demonstrated significant precision advantages over more expensive bioelectrical impedance solutions.

Prism Labs has achieved the delivery of this technology by implementing 3️⃣ key innovations:

1. 👉 While most current 3D body scanning solutions require a rigid subject, Prism's technology allows for scanning of a person in motion, resulting in a more user-friendly experience.

2. 👉 Secondly, unlike other solutions that rely on depth cameras equipped with LIDAR capabilities, Prism's solution utilizes a color camera, reducing the expenses associated with hardware.

3. 👉 Finally, the Prism scanning solution seamlessly incorporates the advanced camera features of the iPhone for skeletal tracking, enhancing the user experience and accuracy. Additionally, it enables easy integration via its mobile SDK with fitness and health solutions like Tempo.

▶️ Diabeloop automates and personalizes the treatment of Type 1 or Type 2 diabetes

Diabeloop (France) provides people living with diabetes with an intelligent therapeutic system to regulate blood 🩸 glucose. This project was initiated in 2011 by the CERITD (Centre d’Études et de Recherches pour l’Intensification du Traitement du Diabète) in collaboration with the CEA LETI (a French government funded technological research organization). After the success of the clinical trials in 2014, Diabeloop was created to bring the project to the market. Since 2021, DBLG1 System, their first automated insulin delivery algorithm, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands, and France.

On January 13, 2026, Diabeloop and Sequel Med Tech announced a collaboration to integrate a new algorithm into the twiist automated insulin pump (Sequel Med Tech, Diabeloop to integrate automated insulin delivery algorithm into twiist pump). In particular

• ✅ The partnership aims to bring DBLG2, Diabeloop’s newest automated insulin delivery (AID) algorithm, to twiist. Sequel offers the twiist AID system that is the first drug delivery system that directly measures the volume of insulin delivered with every microdose.

• ✅ Through the collaboration, Sequel and Diabeloop hope to move twiist closer to a fully closed-loop solution. They plan to make the integrated offering available in the U.S. market initially, potentially followed by global expansion later.

• ✅ Moreover on January 8, 2026, Diabeloop announced that it has received 510(k) clearance from the FDA for DBLG2, as a Class II “Interoperable Automated Glycemic Controller” (iAGC), officially opening the doors of the U.S. market for the company.

Back on July 8, 2025, Diabeloop announced the commercial availability of its DBLG1 algorithm with the Dana-i insulin pump from Sooil (Diabeloop launches insulin delivery algorithm in Germany). The company began its cooperation with Sooil (that produced the first commercially available Insulin Pump in 1980) in February 2020, and they announced a collaboration on automated insulin delivery in 2022.

• ✅ Now Diabeloop and Sooil will distribute their automated insulin delivery offering through Mediq, a leading European diabetes provider. Mediq serves as the exclusive distributor for the DBLG1 system and the Dana-i pump by Sooil.

• ✅ Dana-i, the latest version of the Dana pump, now pairs with the DBLG1 self-learning algorithm for insulin delivery and Mediq plans to support a German rollout in an initial phase for patients already using a Dexcom G6 CGM (a Glucose Monitoring, CGM, System that sends real-time glucose readings automatically to a compatible smart device* or Dexcom receiver).

• ✅ Next steps include launching DBLG2, the version available on smartphones, paired with the latest-generation Dexcom G7.

Finally, in 2023 Diabeloop collaborated with Novo Nordisk to integrate DBL-4pen, Diabeloop’s self-learning algorithm for MDI therapy, with Novo Nordisk’s connected and reusable insulin pens, NovoPen 6 and NovoPen Echo Plus with DBL-4pen (Diabeloop, Novo Nordisk Partner on Next-Gen Insulin Pens).

• ✅ DBL-4pen is a self-learning basal recommendation app for people with Type 1 and Type 2 diabetes who take multiple daily insulin injections (MDI). Multiple Daily Injection (MDI) therapy is an intensive insulin regimen for diabetes management, involving 3–4+ daily injections—typically one or two long-acting basal doses and rapid-acting insulin for meals/corrections.

• ✅ NovoPen 6 and NovoPen Echo Plus are connected pens with a dose memory function that keeps a history of the last 8️⃣0️⃣0️⃣ insulin injections and shows on a built-in digital display the number of units administered during the last injection, as well as the time since that injection.

▶️ Spren Body Scans In Your Smart Phone

Spren (US) is a health technology company that utilizes AI-powered smartphone cameras to provide body composition analysis and metabolic tracking with accuracy comparable to DXA (Dual-energy X-ray Absorptiometry) scans. It is designed for fitness, nutrition, and health monitoring, aiming to make clinical-grade measurements accessible to individuals.

By using just your phone, you get best-in-class accurate body composition, body fat %, lean muscle mass, metabolic rate, heart rate, HRV, respiration rate, and more coming soon. Spren’s platform uses computer vision and machine learning to analyze physiological data from smartphone cameras, often without needing extra, expensive hardware. Key features include:

• ✅ Body Composition Scans: Measures body fat percentage, lean mass, and body fat distribution, with accuracy validated against DXA (dual-energy X-ray absorptiometry) scans.

• ✅ Biomarker Monitoring: Tracks heart rate variability (HRV), resting heart rate, and respiration rate.

• ✅ AI Coaching & Insights: Provides personalized, real-time guidance on fitness, nutrition, and recovery.

• ✅ Health Assessments: Analyzes data to provide insights into cardio-metabolic health and biological age.

On September 23, 2025, Spren announced breakthrough results from a landmark validation study conducted at Pennington Biomedical Research Center, demonstrating that its smartphone camera-based body composition technology achieved gold standard accuracy with unprecedented validation rigor (Spren Achieves Gold Standard Body Composition Accuracy Using Only Your Phone Camera).

• ✅ The study, conducted in partnership with Dr. Steven Heymsfield—the most cited researcher in body composition analysis—validated Spren’s technology against 3️⃣ separate DXA machines from two different manufacturers.

• ✅ The results showed a mean absolute error of 2️⃣.6️⃣% (1️⃣.9️⃣% median) and 0️⃣.9️⃣5️⃣ Pearson correlation, placing Spren’s smartphone app within the natural measurement variability of the machines themselves — out performing most hardware-based solutions as compared to DXA.

• ✅ Spren has served over 1️⃣2️⃣0️⃣ universities and research institutions, processed more than 1️⃣0️⃣0️⃣,0️⃣0️⃣0️⃣ body scans, and analyzed billions of biomarkers.

• ✅ The company recently announced a global partnership with Snap Fitness, demonstrating commercial viability alongside academic validation.

On June 26, 2025, Spren and Snap Fitness, a Lift Brands company operating over 1️⃣,1️⃣0️⃣0️⃣ clubs worldwide, announced a partnership to offer members smartphone-based body composition scanning, and personalized nutrition coaching (Snap Fitness Partners with Spren, Ehancing Tech for 1K+ Gyms).

• ▶️ The partnership addresses a critical gap in the fitness industry: less than 1️⃣0️⃣% of gym members typically work with personal trainers, leaving the remaining 9️⃣0️⃣% without personalized guidance and accurate body composition tracking.

• ▶️ Spren’s technology not only fills this gap but also helps identify members who could benefit from personal training they didn’t know they needed.

▶️ Ultrahuman: the world's most comfortable tracking wearables

Ultrahuman (India) is the world's most comprehensive self-quantification platform.
Ultrahuman’s products include the Ultrahuman Ring AIR–the world’s lightest sleep-tracking 😴 wearable; Ultrahuman M1–a continuous glucose 🍬🩸 monitoring platform; Ultrahuman Home–a home health device 🏠 that monitors environmental markers that affect your health every day; and Blood Vision–a preventive blood 🩸 testing platform with the pioneering UltraTrace™ technology.

• ✅ The Ultrahuman Ring AIR is the world's lightest sleep tracking wearable that accurately measures your sleep, HRV, movement, and temperature, with insights to help you improve your health every day.

• ✅ The Ultrahuman M1 helps you measure the impact of food and activity on your body in real time through glucose as a biomarker.

• ✅ When worn together, the Ring AIR with M1 is uniquely powerful. The glucose data from the M1 in convergence with the movement, body and sleep data from Ring AIR provide deep correlations to improve your metabolic health.

• ✅ The Ultrahuman Home is a silent and sophisticated home health device that monitors environmental markers that affect your health every day, including exposure to artificial light, air quality, humidity, and noise levels. It’s a first for the wearable space to leverage home health data and correlate the home environment (humidity, air quality, temperature) to an individual’s lifestyle (sleep, stress).

• ✅ With Blood Vision, users can do more than just ascertain their current health status. The pioneering UltraTrace™ technology seamlessly correlates changes in your sleep, resting HR, HRV, and movement trends with pertinent markers in the blood.

On January 14, 2026, Ultrahuman partnered with Click Therapeutics, a leader in prescription digital therapeutics, to develop the Migraine PowerPlug.

• ✅ Migraine PowerPlug is a software-based feature within the Ultrahuman platform based on Click Therapeutics’ FDA-authorized prescription digital therapeutic designed to offer both migraine-related insights and guided activities.

• ✅ Migraine PowerPlug will help users track trends across sleep, recovery, stress, and activity, then translate those trends into practical, personalized lifestyle guidance.

• ✅ Plans within Migraine PowerPlug include goals for daily movement, sleep, and even tailored hydration intake recommendations, based on an individual’s migraine patterns.

• ✅ The goal is to deliver more personalized, actionable support to the more than one billion people affected by migraine.

On December 8, 2025, Ultrahuman together with Sleep Cycle, the world’s leading AI sleep technology company, announced the launch of the Respiratory Health PowerPlug for Ultrahuman Ring AIR.

• ✅ For the first time in wearables and smart rings, Ring AIR utilizes high-resolution audio analysis and biomarker data, allowing users to understand how snoring, coughing, and breathing disruptions directly correlate with sleep, recovery, and long-term health outcomes.

Moreover on September 15, 2025, Ultrahuman partnered with Clue, the #1 women-led period and cycle tracker 🌙, to provide women with a more seamless and affordable way to understand their bodies

• ✅ As part of the partnership, every purchase of the Ultrahuman Ring AIR now includes a full year of Clue Plus.

• ✅ Clue Plus unlocks personalized cycle tracking, deeper analysis, advanced predictions, hormone insights, and features designed for pregnancy, perimenopause, and more. It also provides extended 1️⃣2️⃣-month forecasting and expert-backed guidance from clinicians to help users better understand their bodies.

Finally on November 20, 2025, Ultrahuman raised ₹1️⃣0️⃣0️⃣ crore in venture debt from Alteria Capital to support the next stage of its growth.

▶️ Rimidi: Time for better Chronic Disease Management

Rimidi (US) is a clinical management platform designed to integrate remote patient monitoring (RPM) data 🤢😷🏘️, patient-reported outcomes (PROs), and clinical decision support (CDS) directly into electronic health records (EHRs). It provides specialized modules for chronic disease management, including Type 2 Diabetes, hypertension, heart failure, obesity, and nonalcoholic fatty liver disease. Rimidi introduced in 2025 Rimidi 2.0, a next-generation platform enhancement designed to address the increasing complexity of healthcare delivery.

• ▶️ While Rimidi’s platform already enables clients to configure alerts, risk scores, and triage statuses to align with their specific protocols, care team structures, and clinical priorities—such as Remote Patient Monitoring (RPM) and Chronic Care Management (CCM)—Rimidi 2.0 takes these capabilities even further.

• ▶️ With enhanced scalability, strengthened data security, expanded device integration, and a flexible framework designed for the rapid adoption of emerging technologies like AI, the upgraded platform provides both clinical and IT teams with a future-ready solution to optimize patient care, streamline workflows, and improve operational efficiency.

On December 03, 2025, Rimidi partnered with Brevard Health Alliance (BHA), a federally qualified health center in Florida, US, on the implementation of a Remote Patient Monitoring (RPM) program.

• ▶️ The initiative, which utilizes Rimidi’s EHR-integrated platform and connected devices, was launched with support from the State of Florida, Department of Health, through a Cinotti Grant and has demonstrated clinical success that has led to program expansion and improved patient outcomes.

• ▶️ The program has achieved notable results since launching, with 9️⃣5️⃣% of enrolled hypertension patients achieving home blood pressure readings under 1️⃣4️⃣0️⃣/9️⃣0️⃣ during their participation. In fact, in just 2️⃣0️⃣ weeks, BHA has added nearly 2️⃣0️⃣0️⃣ patients to the program, and patients have seen an average improvement of 1️⃣2️⃣mmHg systolic blood pressure and 5️⃣mmHg diastolic blood pressure, with most patients seeing meaningful, sustained improvement at 9️⃣ weeks in the program. This success has allowed BHA to sustain its efforts through RPM reimbursement and expand the scope to include monitoring for high-risk obstetrics patients, with future plans to address other conditions like congestive heart failure and diabetes.

On June 18, 2025, Quest Health Solutions, a national leader in diabetes care and medical device fulfillment, announced compelling results from its Remote Patient Monitoring (RPM) program in partnership with Rimidi.

• ▶️ In just 2️⃣ months, Quest Health RPM Services—powered by Rimidi—led to an 1️⃣1️⃣% improvement in average blood glucose readings among participating patients.

Finally on May 21, 2025, Rimidi announced its partnership with the Salina Family Healthcare Center (SFHC) and its affiliated pharmacist-led hypertension clinic.

• ▶️ As part of its participation in Million Hearts®, SFHC’s clinical goal is to bring 8️⃣0️⃣% of its patients diagnosed with hypertension under control.

▶️ Everly Health parent company of Everlywell

Everly Health (parent company of Everlywell, Natalist, and Everly Health Solutions) provides a comprehensive ecosystem of at-home 🏠, diagnostics-driven, and remote monitoring tools for health tracking. These services combine lab testing, digital insights (like the "WellScore" and "Results Over Time" tracker), and virtual care for Daily Health, Digestive Health, Sexual Health, and Hormone Health.

Everlywell (US) is a digital health company pioneering the next generation of biomarker intelligence—combining AI-powered technology with human insight to deliver personalized, actionable health answers. The company transforms complex biomarker data into life-changing insights, seamlessly integrating advanced diagnostics, virtual care, and patient engagement to reshape how and where health happens.

On October 2, 2025, Everlywell announced the launch of Eva—an AI-powered platform that turns complex biomarker data into easy-to-understand, personalized health insights (Everlywell Launches Next-Gen AI Health Platform Eva to Power Smarter, Scalable Care).

• ✅ Eva is an intelligent health companion that helps personalize crucial touchpoints with smart recommendations and insights throughout the healthcare journey, including an AI-powered engagement model, care plans and clinician support, and CX agents:

  • Eva Engage: AI-powered proactive outreach that connects people at the right time with the right care, automatically scaling personalized health engagement for enterprise partners, including health plans and employers.

  • Eva Care: Smart care coordination that helps create personalized treatment pathways and connects people seamlessly with Everlywell’s affiliated provider network.

  • Eva Support: Comprehensive AI navigator that instantly handles product questions, technical support, account management, and customer service needs.

• ✅ Eva integrates diagnostics, virtual care, and engagement into one seamless, end-to-end experience. With billions of engagement data points, Everlywell’s platform powers predictive outreach and dynamic care plans—fueling measurable outcomes for consumers and efficiency for enterprise partners. Later this year, Everlywell will expand Eva’s capabilities to streamline clinician workflows, including clinical charting and documentation.

▶️ Oura Ring. Smart Ring for Fitness, Stress, Sleep & Health

ŌURA is a Finnish health technology company, known for the Oura Ring, a smart ring used to track sleep 😴 and physical activity 🏄‍♂️. The company was founded in 2013 by Petteri Lahtela, Kari Kivelä, and Markku Koskela.

On October 14, 2025, ŌURA, the company behind the Oura Ring wearable, has raised more than 💲9️⃣0️⃣0️⃣M in funding led by Fidelity Management & Research Company, with participation from ICONIQ, Whale Rock, and Atreides Management (ŌURA valued at $11B following $900M funding round to accelerate global expansion and health technology).

• The round values the company at roughly 💲1️⃣1️⃣ billion.

• Founded in Finland and now headquartered in San Francisco, ŌURA develops data-driven wearable devices that track metrics such as sleep, activity, and heart health.

• The company plans to use the 🆕 funding to advance product development, expand internationally, and invest in AI and new health features. The raise follows a period of rapid growth for ŌURA, which reported 💲5️⃣0️⃣0️⃣M in 2024 revenue and expects to double that figure in 2025.

On January 21 2026, ŌURA and the Centre for Sleep and Cognition (CSC) at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), announced the opening of the Oura–NUS Joint Lab, a 🆕 research entity dedicated to advancing personalized preventive health.

• ✅ Located at NUS, the Joint Lab will advance scientific research by combining continuous, real‑world biometric data from ŌURA within approved research studies with NUS’s decades-long expertise in sleep science, physiological data analysis, and cognitive neuroscience to study how sleep and physical activity shape other areas of health and drive better health outcomes.

• ✅ ŌURA and NUS have collaborated for more than 6️⃣ years across multiple research projects, including evaluating the accuracy of Oura Ring’s sleep tracking, characterizing multi-country differences in nocturnal sleep variability, exploring effects of travel-related sleep disruption and investigating how day‑to‑day shifts in wearable biometric data can inform about cardiovascular health and disease risk.

• ✅ The new Joint lab will expand this work by designing and running multi-year studies that use Oura Ring’s continuous data to understand how real‑world sleep and daily behaviours influence long‑term health outcomes, both at the individual and population levels.